Tetraphase Pharmaceuticals is a biopharmaceutical company using its proprietary chemistry technology to create, develop and commercialize tetracyclines for serious conditions, including bacterial infections caused by multidrug-resistant (MDR) bacteria. Co.'s product, Xerava (eravacycline), is an intravenous, antibiotic for use as a first-line empiric monotherapy for the treatment of MDR infections, including MDR Gram-negative infections, such as those found in complicated intra-abdominal infections. In addition to Xerava, Co. has also developed other fluorocycline antibiotic compounds, TP-6076 and TP-271, and TP-2846, a tetracycline for the treatment of acute myeloid leukemia. The TTPH average annual return since 2013 is shown above.
The Average Annual Return on the TTPH average annual return since 2013 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether TTPH average annual return since 2013 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the TTPH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Video: Don't Forget Dividends in Average Annual Return!
